QYUNS-B Receives Milestone Payment from Roche Following First Patient Dosing in Phase I Trial for QX031N

Stock News

05/27

QYUNS-B (02509) announced that it received a milestone payment from its partner F. Hoffmann-La Roche Ltd (referred to as "Roche") on May 27, 2026. The payment was triggered upon the completion of the first patient dosing in the Phase I clinical trial for the QX031N project (Roche R&D code: RG6981).

QX031N has commenced a Phase I, first-in-human, randomized, double-blind, placebo-controlled, single and multiple ascending dose, parallel-group study in New Zealand. The study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of QX031N in healthy subjects as well as subjects with chronic obstructive pulmonary disease (COPD) and asthma. The first patient in this study was dosed on March 27, 2026.

On October 28, 2025, the company entered into a global exclusive collaboration and license agreement with Roche, granting Roche exclusive worldwide rights to develop, manufacture, and commercialize QX031N.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1162349960"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1162349960\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1162349960?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-27 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162349960","market":"nz","top_or_hot":-1,"title":"QYUNS-B Receives Milestone Payment from Roche Following First Patient Dosing in Phase I Trial for QX031N","media":"Stock News","content":"<p>QYUNS-B (02509) announced that it received a milestone payment from its partner F. Hoffmann-La Roche Ltd (referred to as \"Roche\") on May 27, 2026. The payment was triggered upon the completion of the first patient dosing in the Phase I clinical trial for the QX031N project (Roche R&D code: RG6981).</p>\n<p>QX031N has commenced a Phase I, first-in-human, randomized, double-blind, placebo-controlled, single and multiple ascending dose, parallel-group study in New Zealand. The study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of QX031N in healthy subjects as well as subjects with chronic obstructive pulmonary disease (COPD) and asthma. The first patient in this study was dosed on March 27, 2026.</p>\n<p>On October 28, 2025, the company entered into a global exclusive collaboration and license agreement with Roche, granting Roche exclusive worldwide rights to develop, manufacture, and commercialize QX031N.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>QYUNS-B Receives Milestone Payment from Roche Following First Patient Dosing in Phase I Trial for QX031N</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQYUNS-B Receives Milestone Payment from Roche Following First Patient Dosing in Phase I Trial for QX031N\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-05-27 21:02</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>QYUNS-B (02509) announced that it received a milestone payment from its partner F. Hoffmann-La Roche Ltd (referred to as \"Roche\") on May 27, 2026. The payment was triggered upon the completion of the first patient dosing in the Phase I clinical trial for the QX031N project (Roche R&D code: RG6981).</p>\n<p>QX031N has commenced a Phase I, first-in-human, randomized, double-blind, placebo-controlled, single and multiple ascending dose, parallel-group study in New Zealand. The study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of QX031N in healthy subjects as well as subjects with chronic obstructive pulmonary disease (COPD) and asthma. The first patient in this study was dosed on March 27, 2026.</p>\n<p>On October 28, 2025, the company entered into a global exclusive collaboration and license agreement with Roche, granting Roche exclusive worldwide rights to develop, manufacture, and commercialize QX031N.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02509","symbol_name":"荃信生物-B","start_time":0,"source_url":"","article_id":"1162349960","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162349960","pubTimestamp":1779886961,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"QYUNS-B (02509) announced that it received a milestone payment from its partner F. Hoffmann-La Roche Ltd (referred to as \"Roche\") on May 27, 2026. The payment was triggered upon the completion of the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02509":"荃信生物-B","BK1161":"生物科技"},"translate_title":"QYUNS-B在QX031N I期试验中首次患者给药后收到罗氏的里程碑付款","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02509":1},"content_text":"QYUNS-B (02509) announced that it received a milestone payment from its partner F. Hoffmann-La Roche Ltd (referred to as \"Roche\") on May 27, 2026. The payment was triggered upon the completion of the first patient dosing in the Phase I clinical trial for the QX031N project (Roche R&D code: RG6981).\nQX031N has commenced a Phase I, first-in-human, randomized, double-blind, placebo-controlled, single and multiple ascending dose, parallel-group study in New Zealand. The study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of QX031N in healthy subjects as well as subjects with chronic obstructive pulmonary disease (COPD) and asthma. The first patient in this study was dosed on March 27, 2026.\nOn October 28, 2025, the company entered into a global exclusive collaboration and license agreement with Roche, granting Roche exclusive worldwide rights to develop, manufacture, and commercialize QX031N.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}